Given the marked in vitro synergy of SNDX-50469 or SNDX-5613 combination with venetoclax against AML cells harboring MLL1-r or mtNPM1, we next determined in vivo anti-leukemia efficacy of SNDX-5613 and/or venetoclax at well-tolerated dose levels or their combination in NSG mice engrafted with MOLM13-GFP/Luciferase (Luc) cells [41]. This evidence concerns the gene KMT2A and leukemia.